Translate page

Michael Mauro EHA 2019


The Future of CML Therapy: Unmet Medical Needs and New Treatments in Development
Professor Michael Mauro, Memorial Sloan Kettering Cancer Center New York, USA 

  • Unmet needs in CML: TKI and SCT
  • TKI's in development for CML
  • Development of Asciminib for CML
  • ABL 001X2101: A multicenter, phase 1, first-in-human study
    •  Allosteric inhibition of BCR-ABL
    •  ABL 001X2201: T315l cohort
    • Asciminib phase 3 study Design NCT 03106779
    • Asciminib Phase 2 study design:
      Add-on to first-line imatinib for DMR NCT 03578367
  • PF-114: 3rd generation BCR-ABL

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre